SLXN
Silexion Therapeutics Corp (SLXN)
Healthcare • NASDAQ • $0.16+2.88%
Key Fundamentals
- Symbol
- SLXN
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.16
- Daily Change
- +2.88%
- Market Cap
- $2.21M
- Trailing P/E
- N/A
- Forward P/E
- -0.24
- 52W High
- $36.50
- 52W Low
- $0.15
- Analyst Target
- $5.00
- Dividend Yield
- 0.00%
- Beta
- -0.30
About Silexion Therapeutics Corp
Silexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers. Its products comprise SIL204 second-generation small interfering RNA (siRNA) undergoing phase 2/3 clinical evaluation for pancreatic cancer and silence mutant KRAS oncogene expression. The company was founded in 2008 and is headquartered in Ramat Gan, Israel.
Company websiteResearch SLXN on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.